Genmab — December 2020
-
Epco har ingen grade 3/4, mens Glofitamab havde 1 grade 3 of en grade 4
-
AE hos Glofitamab var primært i de 2 første behandlinger
-
Epco største fordel ligger p.t. ved subcu version, men rygter mener Roche også vil udvikle subcu til Glofitamab
-
Hvis det lykkes, kan det potentielt reducere Glofitamab AEs
-
US svigter igen i dag..:-D
-
Men ind til videre mente Martin Hutchings at Epcoritamab førte racet...
-
GB hvis du kigger her er det over 50% grade 3 eller 4 ? https://twitter.com/graham74GC/status/1335689743347179527/photo/3
-
Men Novo shiner..:-)
-
Peter, I fodnoterne til siden henvises der kun til 2 AEs grade 3 og 4
-
CRS was reported in 63.5% but was only grade 3/4 in severity for 2 patients https://www.onclive.com/view/glofitamab-demonstrates-high-cr-rate-in-relapsed-refractory-nhl
-
evaluate
Vantage -
Odronextamab setback sees Genmab/Abbvie pull ahead https://www.evaluate.com/vantage/articles/events/conferences/ash-2020-igm-averts-disaster-competition-looms -
@Pensionisten et ordentligt brag i min verden er som kun en dags stigning på 120-150 kurs point....så jeg glad...... også støt stigning derfra....... jeg må indrømme jeg føler der er et eller andet i gære med den adfærd som Gmab har for tiden ... men vi får set om der er noget eller det er ønske tænkning.....:-)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind